


RFP-HTLP-2015-001


Intent to Apply (ITA)

A total of four eligible ITA forms were received. A breakdown of eligible ITA forms by disease is shown below:



Full Proposal

A total of four eligible proposals were received. A breakdown of eligible proposals by disease is shown below:



Award Notification

The following four projects were awarded funding.

Project Title	Collaboration Partners	Disease	Intervention	Development Stage	Total Amount
Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai	1. Eisai Co., Ltd. 2. Medicines for Malaria Venture	Malaria	Drug	Hit-to-Lead	¥77,976,000
Identification of lead compounds for anti-TB agent	1. Daiichi Sankyo 2. Global Alliance for TB Drug Development	TB	Drug	Hit-to-Lead	¥90,823,110
Hit-to-Lead Development of anti-TB Phenotypic Screening Hits	1. Shionogi & Co., Ltd. 2. Global Alliance for TB Drug Development 3. The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)	TB	Drug	Hit-to-Lead	¥99,972,033
Antimalarial hits from whole cell screening	1. Medicines for Malaria Venture 2. Takeda Pharmaceutical Company Limited	Malaria	Drug	Hit-to-Lead	¥76,403,334